Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Klarna lands buy now, pay later deal with DoorDash, notching another win ahead of IPO
Klarna is partnering with DoorDash to give users of the restaurant delivery service more ways to pay for their meals.
Why it’s gotten more difficult to get a free first-class upgrade
Airlines are racing to add comforts such as lie-flat seats, entertainment systems with bigger screens and even suites with closing doors.
Toyota is ‘exploring rockets’ with nearly $45 million investment in Japanese launch startup, chairman says
Toyota Motor is exploring the development and production of orbital rockets, Chair CEO Akio Toyoda said Monday.